Skip to content
Company Analysis

Thermo Fisher Scientific Inc TMO

A comprehensive view of key metrics, scores, and financial health for Thermo Fisher Scientific Inc

Overview of Thermo Fisher Scientific Inc.

TMO NYQ
Healthcare Diagnostics & Research Framework: Medical Devices & Diagnostics Large Cap
Thermo Fisher Scientific Inc. (TMO), is a Large Cap company, in the Diagnostics & Research industry, last closed at $469.34, about 56.1% overvalued vs fair value, +16.5% 1Y return, placing in the top 10% of its sector.
Metrics P/E 32.5× Rev Growth 3.9% ROE 13.1% Gross Margin 37.7% Div Yield 0.29%
USD 469.34
-1.33%
(Delayed)
• Vol 90d: 34.7%
52-Week Range
Market Cap
$179.14B
Enterprise Value
$208.67B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 82%
Confidence: 55%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.thermofisher.com
HQ Waltham, MA
Employees 125,000
Fiscal year Dec 31

Next Events

Dividend Jul 15 Ex-div: Jun 15
Earnings Jul 22 Estimated

Fair Value Snapshot

Bear Base Bull
$183
$206
$230
Current: $469.34 -56% vs base

Engine Room Money Flow™

Large Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$44.6B
3.9%%
Gross Profit
$16.8B
-5.2%%
Operating Income (GAAP)
$8.1B
5.1%%
EBITDA
$11.5B
-0.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
37.7%
Fair

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$4.6B
63.1% of Free Cash Flow

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
1
Active Leaks
0/1
Improving
0
High Impact
0
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Thermo Fisher Scientific Inc's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
59
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
33
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing TMO's balance between Growth (22.3%), Profitability (43.1%), and Safety (34.6%). Growth 22% Safety 35% Profitability 43%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

41th percentile vs peers
41
Key Signals
Rev Growth YoY 3.9% 43p EPS Growth YoY 7.8% 37p Revenue CAGR 3Y -0.3% 29p EPS CAGR 3Y 0.3% 49p TSR 11.7% 61p
Strengths
  • Superior capital returns - 3 return metrics above peer median
  • Operating Margin in top 20% of peers (18.2%, 88th percentile)
  • ROIC in top 20% of peers (8.7%, 83th percentile)
Risks

No significant risks identified for this axis.

Profitability

79th percentile vs peers
80
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

64th percentile vs peers
64
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Thermo Fisher Scientific Inc.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$206.14
- - -
-56.1% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000